Advanced SearchSearch Tips
Multiple Myeloma: a Retrospective Analysis of 61 Patients from a Tertiary Care Center
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Multiple Myeloma: a Retrospective Analysis of 61 Patients from a Tertiary Care Center
Sultan, Sadia; Irfan, Syed Mohammed; Parveen, Saira; Ali, Hamza; Basharat, Maria;
  PDF(new window)
Background: Multiple myeloma (MM) is an acquired clonal B-cell malignancy which primarily affects elderly individuals with an annual incidence of approximately 1% of all malignancies. Our aim is to study demographic and clinicopathological features of adult Pakistani MM patients at presentation. Materials and Methods: This single centre retrospective study extended from January 2010 to December 2014. Data were retrieved from the patients` maintained records on predetermined performa. Results: Overall, 61 patients were diagnosed at our institution with MM during the study period. There were 43 males and 18 females. Age ranged between 34 and 81 years with a mean of and a median of 57 years. The male to female ratio was ~2:1. Common presenting complaints included fatigue (81.9%), backache (80.3%) and bone pain (67.2%). Physical findings revealed pallor (44.2%) as a presenting clinical feature. The mean hemoglobin value was with a mean MCV of . Severe anemia with hemoglobin <8.5 gm/dl was seen in 40.9%. The mean total leukocyte count was , the ANC was and the mean platelet count was . Conclusions: MM in Pakistani patients is seen in a relatively young population with male preponderance. The majority of patients present with symptomatic anemia and backache to seek medical attention. However, clinico-pathological features appear comparable to the published literature.
Multiple myeloma;demographic data;Pakistan;
 Cited by
Combined therapeutic effects of bortezomib and anacardic acid on multiple myeloma cells via activation of the endoplasmic reticulum stress response, Molecular Medicine Reports, 2016, 14, 3, 2679  crossref(new windwow)
Basit A, Siddiqui N, Hameed A, et al (2014). Factors affecting outcome of patients with multiple myeloma. J Ayub Med Coll Abottabad, 26, 376-9.

Eriksson M, Karisson M (1992). Occupational and other environ mental factors and multiple niycolma: a population based case-control study. Br1, Ind Med, 49, 95-103.

Inam ullah, Raziq F, Tahir M, Wazir R, Rafiq A (2010). Hematological Presentation of Multiple Myeloma in Khyber Pakhtunkhwa. Gomal J Med Sciences, 8, 130-3.

Kaur P, Shah BS, Baja P (2014). Multiple myeloma: a clinical and pathological profile. Gulf J Oncolog, 1, 14-20.

Kyle RA, Gertz MA, Witzig TE, et al (2003). Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proc, 78, 21-33. crossref(new window)

Landgren O, Weiss BM (2009). Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia, 23, 1691-7. crossref(new window)

McKenna RW, Kyle RA, Kuehl WM, et al (2008). WHO classification of tumours of haemopoietic and lymphoid tissues. Lyon: International Agency Res Cancer, 202.

Mehdi WA, Zainulabdeen JA, Mehde AA (2013). Investigation of the antioxidant status in multiple myeloma patients: effects of therapy. Asian Pac J Cancer Prev, 14, 3663-7. crossref(new window)

Mansoor S, Siddiqui I, Adil S, Kakapeto GN, Fatmi Z (2005). Frequency of hypercalcemia in patients of multiple myeloma in Karachi. J Coll Physicians Surg Pak, 15, 409-12.

Mansoor S, Siddiqui I, Adil S, et al (2007). Anion gap among patients of multiple myeloma and normal individuals. Clin Biochem, 40, 226-9. crossref(new window)

Mohammadi M, Cao Y, Glimelius I, et al (2015) .The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma - a Swedish population-based study. BMC Cancer, 15, 850. crossref(new window)

Omoti CE, Nwannadi AI, Obieche JC, Olu-Eddo AN (2012). The epidemiological features of lymphoid malignancies in Benin City, Nigeria: a 15 years study. Pan Afr Med J, 11, 10.

Rajkumar SV (2011). Treatment of multiple myeloma. Nat Rev Clin Oncol, 8, 479-91. crossref(new window)

Shaheen H, Ghanghroo I, Malik I (1999). Clinicopathological features and management of Pakistani patients with multiple myeloma. J Pak Med Assoc, 4, 233-7.

Sashidharan N, Shenoy S, Kishore MK, Thanusubramanian H (2015). Comparison of two therapeutic regimes, lenalidomide with dexamethasone and thalidomide with dexamethasone, in the treatment of multiple myeloma at a tertiary care hospital in India. J Clin Diagn Res, 9, 1-4. crossref(new window)

Sun JJ, Zhang C, Zhou J, Yang HL (2015). Pooled analysis of pomalidomide for treating patients with multiple myeloma. Asian Pac J Cancer Prev, 16, 3163-6. crossref(new window)

Sutandyo N, Firna E, Agustina J, et al (2015). Clinicopathology profile and bone involvement of multiple myeloma patients in dharmais national cancer hospital, indonesia. Asian Pac J Cancer Prev, 16, 6261-5. crossref(new window)

Subramanian R, Basu D, Dutta TK (2009). Prognostic significance of bone marrow histology in multiple myeloma. Indian J Cancer, 46, 40-5. crossref(new window)

Vincent Rajkumar S (2014). Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management. Am J Hematol, 89, 999-1009.

Wang L, Wang KF, Chang BY, Chen XQ, Xia ZJ (2015). Once-weekly subcutaneous administration of bortezomib in patients with multiple myeloma. Asian Pac J Cancer Prev, 16, 2093-8. crossref(new window)

Yassin AK (2013). Clinical and Laboratory Profiles of 109 Patients diagnosed as Multiple Myeloma in Erbil City. J Fac Med Baghdad, 55, 121-4.